Advanced search
Publication Cover
Pediatric Health Volume 4, 2010 - Issue 1
Journal homepage
169
Views
0
CrossRef citations to date
0
Altmetric
Review

Role of β-Blocker Therapy in Pediatric Heart Failure

Akash R Patela The Children’s Hospital of Philadelphia, Department of Cardiology, 34th & Civic Center Boulevard, Philadelphia, PA19104, USA Tel.: +1 215 590 3548 Fax.: +1 215 590 [email protected]View further author information
&
Robert E Shaddyb The Children’s Hospital of Philadelphia, Department of Cardiology, 34th & Civic Center Boulevard, Philadelphia, PA19104, USA Tel.: +1 267 426 7518 Fax.: +1 267 426 [email protected]Correspondence[email protected]
View further author information
Pages 45-58 | Published online: 25 Jan 2010

Bibliography

  • Towbin JA , LoweAM, ColanSD, SleeperLAet al.: Incidence, causes and outcomes of dilated cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry.JAMA296(15), 1867–1876(2006).
  • Nugent AW , DaubeneyPE, ChondrosPet al.: The epidemiology of childhood cardiomyopathy in Australia.N. Engl. J. Med.(348), 1639–1646(2003).
  • Hoffman J , KaplanS: The incidence of congenital heart disease.J. Am. Coll. Cardiol.39(12), 1890–1900(2002).
  • Kay JD , ColanSD, GrahamTP: Congestive heart failure in pediatric patients.Am. Heart J.142(5), 923–928(2001).
  • Kirk R , EdwardsLB, AuroraPet al.: Registry of the Internation Society of of Heart and Lung Transplantation: Eleventh Official Pediatric Heart Transplantation Report – 2008.J. Heart Lung Transplant.27(9), 970–977(2008).
  • Harmon WG , SleeperLA, CunibertiLet al.: Treating children with idiopathic dilated cardiomyopathy (from the Pediatric Cardiomyopathy Registry).Am. J. Cardiol.104(2), 281–286(2009).
  • Rosenthal D , ChrisantM, EdenEet al.: International Society for Heart and Lung Transplantion: Practice guidelines for management of heart failure in children.J. Heart Lung Transplant.23(12), 1313–1333(2004)
  • Shaddy RE : Paediatric heart failure trials and tribulations.Cardiol. Young17, 354–355(2007).
  • Bristow MR : Mechanisms of action of β-blocking agents in heart failure.Am. J. Cardiol.80(11A), 26L–40L (1997).
  • Cohn JN , FerrariR, SharpeN: Cardiac remodeling-concepts and clinical implications: a concensus paper from an international forum on cardiac remodeling. behalf of an International Forum on Cardiac Remodeling.J. Am. Coll. Cardiol.35(3), 569–582(2000).
  • Colucci WS , SawyerDB, SinghK, CommunalC: Adrenergic overload and apoptosis in heart failure: implications for therapy.J. Card. Fail.6(2 Suppl. 1), 1–7(2000).
  • Port JD , BristowMR: Altered β-adrenergic receptor gene regulation and signaling in chronic heart failure.J. Mol. Cell. Cardiol.33(5), 887–905(2001).
  • Floras J : Sympathetic nervous system activiation in human heart failure: clinical implications of an updated model.J. Am. Coll. Cardiol.54(5), 375–385(2009).
  • Gilbert EM , AndersonJL, DeitchmanDet al.: Long-term β blocker vasodilator therapy improves cardiac function idiopathic dilated cardiomyopathy: a double-blinded randomized study of bucindolol vs. placebo.Am. J. Med.88(3), 223–228(1990).
  • Waagstein F , BristowMR, SwedbergKet al.: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial.Lancet342(8885), 1441–1446(1993).
  • CIBIS Investigators: A randomized trial of β-blockers in heart failure. The Cardiac Insufficiency Bisoprolol Study. Circulation90, 1765–1773(1994).
  • Bristow MR , GilbertEM, AbrahamWT: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.Circulation94(11), 2807–2816(1996).
  • Colucci WS , PackerM, BristowMRet al.: Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.Circulation94(11), 2800–2806(1996).
  • Packer M , BristowMR, CohnJNet al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure.N. Engl. J. Med.334(21), 1349–1355(1996).
  • Packer M , ColluciWS, Sankner-BernsteinJDet al.: Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective randomized evaluation of carvedilol on symptoms and exercise.Circulation94(11), 2793–2799(1996).
  • Lechat P , EscolanoS, GolmardJLet al.: Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol study (CIBIS).Circulation96, 2197–2205(1997).
  • CIBIS II Investigators: The Cardiac Insufficiency Bisoprolol study (CIBIS-II). Lancet353, 9–13(1999).
  • Hjalmarson A , GoldsteinS, FagerbergBet al.: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure.Lancet353, 2001–2007(1999).
  • Hialmarson A , GoldsteinS, FagerbergBet al.: Effect of controlled-release metoprolol on total mortality, hospitalization and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure MERIT-HF Study Group.JAMA283, 1295–1302(2000).
  • Fowler MB , Vera-LlnchM, OsterGet al.: Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group.J. Am. Coll. Cardiol.37, 1692–1699(2001).
  • Packer M , CoatsAJ, FowlerMBet al.: Effect of carvedilol on survival in severe chronic heart failure. Carvedilol Prospective Randomized Cumulative Survival study group.N. Engl. J. Med.344(22), 1651–1658(2001).
  • BEST Trial Investigators: A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med.344(22), 1659–1667(2001).
  • Leizorovicz A , LechatP, CucheratMet al.: Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies – CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study.Am. Heart J.143, 301–307(2002).
  • Packer M , FowlerMB, RoeckerEBet al.: Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study group.Circulation106, 2194–2199(2002).
  • Poole-Wilson PA , SwedbergK, ClelandJGet al.: Comparison of carvedilol and metroprolol on clincial outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized control trial.Lancet362, 7–13(2003).
  • Poole-Wilson PA : Commentary on the Carvedilol or Metoprolol European Trial (COMET).Am J Cardiology.93(9A), 40B–2B (2004).
  • Flather MD , ShibataMC, CoatsAJet al.: Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).Eur. Heart J.26(3), 215–225(2005).
  • Mann DL , BristowMR: Mechanisms and models in heart failure: the biomechanical model and beyond.Circulation111, 2837–2849(2005).
  • Bristow MR , GinsburgR, UmansVet al.: β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes in muscle contraction and selective β1-receptor down-regulation in heart failure.Circ. Res.59(3), 297–309(1986).
  • Patel PA , TilleyDG, RockmanHA: β-arrestin-mediated signaling in the heart.Circ. J.72, 1725–1729(2008).
  • Pleger ST , BoucherM, MostP, KochWJ: Targeting myocardial β-adrenergic receptor signaling and calcium cycling for heart failure gene therapy.J. Cardiac Fail.13, 401–414(2007).
  • Gauthier C , TavernierGC, LanginD, Le Marec H: Functional β3-adrenoceptor in the human heart. Clin. Invest.98, 556–562(1996).
  • Gauthier C , Seze-GoismierC, RozeeB: β-3 adrenoreceptors in the cardiovascular system.Clin. Hemrheol. Microcirc.37, 193–204(2007).
  • Liggett SB , FreedmanNJ, SchwinnDA, LefkowitzRJ: Structural basis for receptor subtype-specific regulation revealed by a chimeric β-3/β-2 adrenergic receptor.Proc. Natl Acad. Sci.90, 3665–3669(1993).
  • Hort W : Quantitative histologische untersuchungen an wachsenden herzen.Virchows Arch.323, 223–242(1953).
  • Zak R : Development and proliferative capacity of cardiac muscle cells.Circ. Res.35, 17–26(1974).
  • Mahony L : Development of myocardial structure and function. In: Moss and Adams’ Heart Disease in Infants, Children, and Adolescents (7th Edition, Volume 1). Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (Eds). Lippincott Williams & Wilkins, PA, USA, 573–592(2008).
  • Wittnich C , BelangerMP, BandaliK: Are there ventricle-specific postnatal maturational differences in myocardial β-adrenoceptors?Can. J. Physiol. Pharmacol.84, 859–865(2006).
  • Teitel DF , SidiD, ChinT: Developmental changes in myocardial contractile reserve in the lamb.Pediatr. Res.19(9), 948–955(1985).
  • Kozlik R , KramerHH, WichtH, KrianA, OstermeyerJ, ReinhardtD: Myocardial β-adrenoreceptor density and the distribution of β1- and β2-adrenoreceptor subpopulations in children with congenital heart disease.Eur. J. Pediatr.150, 388–394(1991).
  • Kozlik R , KramerHH, WichtH, BircksW, ReinhardtD: β-adrenoreceptor density on mononuclear leukocytes and right atrial myocardium in infants and children with congenital heart disease.Klin. Wochenschr.69, 910–916(1991).
  • Kozlik-Feldman R , KramerHH, WichtH, FeldmannR, NetzH, ReinhardtD: Distribution of myocardial β-adrenoceptor subtypes and coupling to the adenylate cyclase in children with congenital heart disease and implications for treatment.J. Clin. Pharmacol.33(7), 588–595(1993).
  • Dzimiri N , GalalO, MoorjiAet al.: Regulation of sympathetic activity in children with various congenital heart diseases.Pediatr. Res.38(1), 55–60(1995).
  • Wu JR , ChangHR, HuangTY, ChiangCH, ChenSS: Reduction in lymphocyte β-adrenergic receptor density in infants and children with heart failure secondary to congenital heart disease.Am. J. Cardiol.77, 170–174(1996).
  • Reithmann C , ReberD, Kozlik-FeldmannRet al.: A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease.Eur. J. Pharmacol.330, 79–86(1997).
  • Ohuchi H , HasegawaS, YasudaKet al.: Severly impaired cardiac autonomic nervous activity after the Fontan operation.Circulation104, 1513–1518(2001).
  • Buchhorn R , Hulpke-WetteM, RuschewskiWet al.: β-receptor downregulation in congenital heart disease: a risk factor for complications after surgical repair?Ann. Thorac. Surg.73(2), 610–613(2002).
  • Davos CH , DavlourosPA, WenselRet al.: Global impairment of cardiac autonomic nervous activity late after repair of Tetralogy of Fallot.Circulation106(12 Suppl. 1), I69–75(2002).
  • Bolger AP , SharmaR, LiWet al.: Neurohormal activiation and the chronic heart failure syndrome in adults with congenital heart disease.Circulation106(1), 92–99(2002).
  • Davos CH , FrancisDP, LeenartsMFet al.: Global impairment of cardiac autonomic nervous activity later after the Fontan operation.Circulation108(Suppl. 1), II80–II85 (2003).
  • Kaufman BD , DesaiM, ReddySet al.: Genomic profiling of left and right ventricular hypertrophy in congenital heart disease.J. Cardiac Fail.14(9), 760–767(2008)
  • Kalay N , BasarE, OzdogruIet al.: Protective effects of carvedilol against anthracycline-induced cardiomyopathy.J. Am. Coll. Cardiol.48, 2258–2262(2006).
  • Stock JP : β adrenergic blocking drugs in the clinical management of cardiac arrhythmias.Am. J. Cardiol.18, 444–449(1966).
  • Hunt SA , AbrahamW, ChinMet al.: ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult.Circulation112, E154–E235 (2005).
  • Bruns LA , CanterCE: Should β-blockers be used for the treatment of pediatric patients with chronic heart failure?Pediatr. Drugs4(12), 771–778(2002).
  • Foerster SR , CanterCE: Pediatric heart failure therapy with β-adrenoceptor antagonists.Pediatr. Drugs10(2), 125–134(2008).
  • Zebrack JS , MungerM, MacGregorJ, LombardiWL, StoddardGP, GilbertEM: β-receptor Selectivity of Carvedilol and Metoprolol Succinate in Patients with Heart Failure (SELECT trial): a randomized dose-ranging trial.Pharmacotherapy29(8), 883–890(2009).
  • Keating G , JarvisB: Carvedilol: a review of its use in chronic heart failure.Drugs63(16), 1697–1741(2003).
  • Okafor CC , Perreault-MicaleC, HajjarRJet al.: Chronic treatment with carvedilol improves ventricular function and reduces myocyte apoptosis in an animal model of heart failure.BMC Physiol.3(6), 1–9(2003).
  • Gielser G , LenihanDJ, DurandJBet al.: The update on the rationale, use and selection of β-blockers in heart failure.Curr. Opin. Cardiol.19, 250–253(2004).
  • Udelson JE : Ventricular remodeling in heart failure and the effect of β-blockade.Am. J. Cardiol.93(9 Suppl. 1), 43–48(2004).
  • Al-Hesayan A , AzevedoE, FlorasJet al.: Selective versus nonselective β-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization.Eur. J. Heart Fail.7, 618–623(2005).
  • Andreka P , AiyarN, OlsonLCet al.: Bucindolol displays intrinsic sympathomimetic activity in human myocardium.Circulation105, 2429–2434(2002).
  • Gan RT , LiWM, XiuCH: Chronic blocking of β 3-adrenoreceptor ameliorates cardiac function in rat model of heartfailure.Chinese Med. J.120(24), 2250–2255(2007).
  • Moniette S , BalligandJL: Potential use of β(3)-adrenoreceptor antagonists in heart failure therapy.Cardiovasc. Drug Rev.20(1), 19–26(2002).
  • Greenway SC , BensonLN: The use of carvedilol in pediatric heart failure.Cardiovasc. Hematol. Disord. Drug Targets6, 35–42(2006).
  • Laer S , MirTS, BehnFet al.: Carvedilol therapy in pedatric pateints with congestive heart failure: a study investigating clincal and pharmocokinetic parameters.Am. Heart J.143(5), 916–922(2002).
  • Albers S , MeibohmB, MirT, LaerS: Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure.Br. J. Clin. Pharmacol.65(4), 511–522(2007).
  • Azuma J , NonenS: Chronic heart failure: β-blockers and pharmacogenetics.Eur. J. Clin. Pharmacol.63, 3–17(2009).
  • Taylor MR : Pharmacogenetics of the human β-adrenergic receptors.Pharmacogenetics J.7, 29–37(2007).
  • Dorn GW , LiggettSB: Mechanisms of pharmacogenomic effects of genetic variation within the cardiac adrenergic network in heart failure.Mol. Pharm.76, 466–480(2009).
  • Wagoner LE , CraftLL, ZengelP: Polymorphisms of the β1-adrenergic receptor predict exercise capacity in heart failure.Am. Heart J.144, 840–846(2002).
  • Mialet Perez J , RathzDA, PetrashevskayaNN: β1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure.Nat. Med.9, 1300–1305(2003).
  • Molenaar P , ChenL, SemmlerABet al.: Human heart β-adrenoreceptors: β1-adrenoreceptor diversification through affinity states’ and polymorphism.Clin. Exp. Pharmacol. Physiol.34, 1020–1028(2007).
  • Liggett S , Mialet-PerezJ, Thaneemit-ChenS: A polymorphism within a conserved β1 adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure.Proc. Natl Acad. Sci.103, 11288–11293(2006).
  • White HL , de Boer RA, Maqbool A: An evaluation of the β1-adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-st. Eur. J. Heart Fail.5, 463–468(2003).
  • de Groote P , LamblinN, HelbecqueNet al.: The impact of β-adrenoreceptor gene polymorphisms on survival in patients with congestive heart failure.Eur. J. Heart Fail.7(6), 966–973(2005).
  • Sehnert AJ , DanielsSE, ElashoffMet al.: Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol and metoprolol.J. Am. Coll. Cardiol.52, 644–651(2008).
  • Packer M , AntonopoulosGV, BerlinJA, ChittamsJ, KonstamMA, UnderlsonJE: Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis.Am. Heart J.141(6), 899–907(2001).
  • Buchorn R , BartmusD, SiekmeyerW, Hulpke-WetteM, SchulzR, BurschJ: β-blocker therapy of severe congestiveheart failure in infants with left to right shunts.Am. J. Cardiol.81(11), 366–368(1998).
  • Buchhorn R , Hulpke-WetteM, HilgersR, BartmusD, WesselA, BurschJ: Propranolol treatment of congestive heart failure in infants with congenital heart disease: the CHF-PRO-INFANT Trial. Congestive heart failure in infants treated with propranolol.Int. J. Cardiol.79, 167–173(2001).
  • Buchhorn R , Hulpke-WetteM, RuschewskiW: Effects of therapeutic β blockade on myocardial function and cardiac remodeling in congenital cardiac disease.Cardiol. Young.13(1), 36–43(2003).
  • Shaddy RE , OlsenSL, BristowMRet al.: Efficacy and safety of metoprolol in the treatment of doxorubicin-induced cardiomyopathy in pediatric patients.Am. Heart J.129(1), 197–199(1995).
  • Shaddy RE : β-blocker therapy in young children with congestive heart failure under consideration for heart transplantation.Am. Heart J.136(1), 19–21(1998).
  • Shaddy RE , TaniLY, GiddingSSet al.: β-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience.J. Heart Lung Transplant.18(3), 269–274(1999).
  • Metra M , GiubbiniR, NodariS, BoldiE, ModenaMG, Dei Cas L: Differential effects of β-blockers in patients with heart failure: a prospective, randomized, double-blinded comparision of the long-term effects of metoprolol versus carvedilol. Circulation102(5), 546–551(2000).
  • Sanderson JE , ChanSK, YipGet al.: β-blockade in heart failure: a comparison of carvedilol with metoprolol.J. Am. Coll. Cardiol.34(5), 1522–1528(1999).
  • Williams RV , TaniLY, ShaddyRE: Intermediate effects of treatment with metoprolol or carvedilol in children with left ventricular systolic dsyfunction.J. Heart Lung Transplant.21(8), 906–909(2002).
  • Bruns LA , ChrisantMK, LamourJMet al.: Carvedilol as a therapy in pediatric heart failure: an inital multicenter experience.J. Pediatr.138(4), 505–511(2001).
  • Gachara N , PrabhakaranS, SrinivasS, FarzanaF, KrishanU, ShahM: Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a prelimanary report.Indian Heart J.53(1), 74–78(2001).
  • Lee KJ : Carvedilol in heart failure management: a pediatric experience.Can. J. Cardiology17(Suppl. C), 100C (2001).
  • Rusconi P , Gomez-MarinO, Rossique-GonzalezMet al.: Carvedilol in children with cardiomyopathy: 3 -year experience at a single institution.J. Heart Lung Transplant.23(7), 832–838(2004).
  • Azeka E , Franchini Ramires JA, Valler C, Alcides Bocchi E: Delisting of infants and children from the heart transplantation waiting list after carvedilol treatment. J. Am. Coll. Cardiol.40(11), 2034–2038(2002).
  • Blume ED , CanterCE, SpicerR, GauvreauK, ColanS, JenkinsKJ: Prospective single-arm protocol of carvedilol in children with ventricular dysfunction.Pediatric Cardiol.27(3), 326–342(2006).
  • Shaddy RE , BoucekMM, HsuDTet al.: Carvedilol for children and adolescents with heart failure.JAMA298(10), 1171–1179(2007).
  • Bajcetic M , KokicA, DjukicMet al.: Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.Clin. Ther.30(4), 702–714(2008).
  • Vonder Muhll I , LiuP, WebbG: Applying standard therapies to new targets: the use of ACE inhibitors and β-blockers for heart failure in adults with congenital heart disease.Int. J. Cardiol.97(Suppl. 1), 25–33(2004).
  • Lindenfeld J , KellerK, CampbellDet al.: Improved systemic ventricular function afer carvedilol adminstration in a patient with congenitally corrected transposition of the great arteries.J. Heart Lung Transplant.22, 198–201(2003).
  • Josephson C , HowlettJ, JacksonSet al.: A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of β-blockade.Can. J. Cardiol.22(9), 769–772(2006).
  • Doughan AR , McConnellME, BookWM: Effect of β-blockers (carvedilol or metroprolol XL) in patients with transposition of great Arteries and dysfunction of the systemic right ventricle.Am. J. Cardiol.99(5), 704–706(2007).
  • McAlister FA , EzekowitzJ, HootonNet al.: Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: a systemic review.JAMA297(22), 2502–2514(2007).
  • Veldtman GR , NishimotoA, SiuSet al.: The Fontan procedure in adults.Heart86, 330–335(2001).
  • Gelatt M , HamiltonRM, McCrindleBWet al.: Arrhythmia and mortality following the mustard procedure: a 30 year, single center experience.J. Am. Coll. Cardiol.29, 194–201(1997).
  • Grahram TP , BernardYD, MellenBGet al.: Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study.J. Am. Coll. Cardiol.36, 255–261(2000).
  • Millane T , BernardEJ, JaeggiEet al.: Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposition of the great arteries.J. Am. Coll. Cardiol.35, 1661–1668(2000).
  • Piran S , VeldtmanG, SiuSet al.: Heart Failure and ventricular dysfunction in patients with single or systemic right ventricles.Circulation105, 1189–1194(2002).
  • Rutledge JM , NihillMR, FraserCDet al.: Outcome of 121 patients wtih congenitally corrected transposition of the great arteries.Pediatr. Cardiol.23, 137–145(2002).
  • Eicken A , FratzS, GutfriedCet al.: Hearts late after Fontan have normal mass, normal volume, and reduced systolic function.J. Am. Coll. Card.42(6), 1061–1065(2003).
  • Ishibashi N , ParkIS, TakahashiYet al.: Effectiveness of carvedilol for congestive heart failure that developed long after modified Fontan operation.Pediatr. Cardiol.27(4), 473–475(2006).
  • Norozi K , BahlmannJ, RaabBet al.: A prospective, randomized, double-blinded, placebo controlled trial of β-blockade in patients who have undergone surgical correction of Tetralogy of Fallot.Cardiol. Young.17, 372–379(2007).
  • Nororzi K , BuchhornR, WesselAet al.: β-blockade does not alter plasma cytokine concentrations and ventricular function in young adults with right ventricular dysfunction secondary to operated congenital heart disease.Circ. J.72, 747–752(2008).
  • Mukai Y , YoshidaT, NakaiakeRet al.: Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol.Intern. Med.43(11), 1087–1088(2004).
  • Carreira RS , MonteiroLM, GoncalvesLM, ProvidenciaLA: Carvedilol: just another β-blocker or a powerful cardioprotector?Cardiovasc. Hematol. Disord. Drug Targets6, 257–266(2006).
  • Machado V , CabralA, MonteiroPet al.: Carvedilol as a protector againstthe cardiotoxicity induced by antracyclines (doxorubicin).Revista Portuguesa de Cardiologia27(10), 1277–1296(2008).
  • Ishikawa Y , BachJ, MinamiR: Cardioprotection for Duchenne‘s muscular dystrophy.Am. Heart J.137, 895–902(1999).
  • Kajimoto H , IshigakiK, OkumuraKet al.: β-blocker therapy for cardiac dysfunction in patients with muscular dystrophy.Circ. J.70, 991–994(2006).
  • Nishizawa T , YasumaF: The preventive efficacy of carvedilol on cardiac dysfunction in duchenne muscular dystrophy. clinicaltrials.gov indentifier: Current Study NCT00606775, 2007–2012.
  • Hunt SA , AbrahamWT, ChinMHet al.: 2009 Focused update incorporatedinto the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation119, E391–E479 (2009).
  • Kaufman BD , ShaddyRE: β-adrenergic receptor blockade and pediatric dilated cardiomyopathy.Prog. Pediatr. Cardiol.24(1), 51–57(2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.